Aadil Abowath
Diamond Bar, CANPI 1790238962
Payments from drug & device makers
Across 441 payments — averaging $21.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$1K
- AbbVie$908
- LEO Pharma Inc.$907
- Lilly USA, LLC$883
- Sanofi$836
- Regeneron Healthcare Solutions, Inc.$785
- plus $4K from 22 others
What the payments were for
- Speaking & faculty fees$1091%
- Food & beverage$9,21795%
- Education$3604%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 57 | $1,163 |
| AbbVie | 50 | $908 |
| LEO Pharma Inc. | 48 | $907 |
| Lilly USA, LLC | 30 | $883 |
| Sanofi | 28 | $836 |
| Regeneron Healthcare Solutions, Inc. | 26 | $785 |
| Amgen | 22 | $668 |
| Pfizer | 39 | $630 |
| Novartis | 30 | $568 |
| Johnson & Johnson | 15 | $429 |
| Galderma Laboratories, L.p. | 28 | $326 |
| Sun Pharmaceutical Industries Inc. | 11 | $316 |
| Arcutis Biotherapeutics, Inc. | 13 | $245 |
| UCB, Inc. | 8 | $205 |
| Strata Skin Sciences, Inc. | 4 | $168 |
| Mayne Pharma Commercial LLC | 16 | $150 |
| Janssen Scientific Affairs, LLC | 1 | $123 |
| EPI Health, LLC | 2 | $120 |
| E.r. Squibb & Sons, L.L.C. | 2 | $45 |
| Merz North America, Inc. | 1 | $40 |
| Botanix SB Inc | 1 | $33 |
| LNHC, Inc | 1 | $24 |
| Biofrontera Inc. | 2 | $24 |
| Organon | 2 | $23 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $18 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $17 |
| Dermavant Sciences, Inc. | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 24 | $86,173 |
| Dupixent PenDupilumab | 11 | $40,048 |
| Ketoconazole | 195 | $2,897 |
| Clobetasol Propionate | 73 | $2,798 |
| Tacrolimus | 30 | $2,372 |
| Fluorouracil | 40 | $2,160 |
| Fluocinonide | 49 | $1,656 |
| Tretinoin | 27 | $967 |
| Doxycycline Hyclate | 66 | $639 |
| Ciclopirox | 19 | $510 |
| Clindamycin Phosphate | 19 | $432 |
| Triamcinolone Acetonide | 91 | $394 |
| Desonide | 15 | $331 |
| Hydroxyzine Hcl | 41 | $317 |
| Ammonium Lactate | 17 | $271 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.